Treatment of metastatic breast cancer with aminoglutethimide.

Author: AsburyR F, BakemeierR F, BennettJ M, FölschE, McCuneC S, SavlovE

Paper Details 
Original Abstract of the Article :
Seventy-three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone. No complete responses occurred. Ten patients (16%) achieved partial responses (mean duration, 12 months). The proportions of patients responding by disease site were breast (50%), nodes (33%), sk...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1002/1097-0142(19810415)47:8<1954::aid-cncr2820470807>3.0.co;2-e

データ提供:米国国立医学図書館(NLM)

Tackling Metastatic Breast Cancer with Aminoglutethimide

The world of oncology is a vast desert, with researchers constantly searching for new oases of hope. This research focuses on metastatic breast cancer, a challenging condition that often requires multifaceted treatment approaches. The study delves into the effectiveness of aminoglutethimide, a medication that disrupts hormone production, in combination with dexamethasone, a corticosteroid used to manage side effects. The researchers used a rigorous approach, observing the outcomes of 73 women with metastatic breast cancer. Their findings, like shimmering pools in the desert, indicate that this treatment combination can be an effective tool in the fight against this disease.

Promising Results in the Desert of Metastatic Breast Cancer

The results of this study, like a caravan arriving at a lush oasis, bring a sense of relief and hope. While complete responses were not observed, a remarkable 16% of patients experienced partial responses, with a mean duration of 12 months. This is a significant achievement, considering the challenges of treating metastatic disease. The researchers also noted that the effectiveness of the treatment varied across different disease sites, with the breast, nodes, and skin showing particularly promising responses.

Navigating the Side Effects of Treatment

Like the desert, cancer treatment can be harsh and unforgiving, with side effects often presenting a challenge. This study highlights the importance of considering these side effects, with 75% of patients experiencing some form of adverse reaction. While the side effects were manageable in most cases, they did lead to discontinuation of therapy in a small number of patients. However, the researchers emphasize that the benefits of this treatment, like a cool breeze in the desert, outweigh the risks for many patients.

Dr.Camel's Conclusion

This study, like a well-traveled path through the desert, offers valuable insights into the treatment of metastatic breast cancer. Aminoglutethimide in combination with dexamethasone emerges as a potentially effective weapon in the fight against this disease. However, it's important to remember that each patient's journey is unique, and personalized care is essential. We must continue to explore the vast landscape of cancer research, seeking new oases of hope for patients battling this challenging disease.

Date :
  1. Date Completed 1981-07-23
  2. Date Revised 2019-06-20
Further Info :

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.